Brainstorm Cell Therapeutics Inc. (BCLI) Could Burn Your Portfolio. The Stock Formed Multiple Bottom Pattern

June 12, 2018 - By Adrian Erickson

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

The stock of Brainstorm Cell Therapeutics Inc. (BCLI) shows a multiple bottoms pattern with $4.23 target or 8.00 % below today’s $4.60 share price. The 7 months chart pattern indicates high risk for the $87.91M company. It was reported on Jun, 12 by Finviz.com. If the $4.23 price target is reached, the company will be worth $7.03 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 0.43% or $0.02 during the last trading session, reaching $4.6. About 138,583 shares traded or 3.20% up from the average. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has risen 14.11% since June 12, 2017 and is uptrending. It has outperformed by 1.54% the S&P500.

Analysts await Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings on August, 13. They expect $-0.14 earnings per share, down 133.33 % or $0.08 from last year’s $-0.06 per share. After $-0.12 actual earnings per share reported by Brainstorm Cell Therapeutics Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

More recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: Streetinsider.com which released: “Brainstorm Cell Therapeutics (BCLI) Releases Statement on ‘Right to Try’ Legislation” on May 25, 2018. Also Prnewswire.com published the news titled: “BrainStorm to Host Call Following President Trump’s Citing of Company’s ALS Treatment During “Right-to-Try” Bill …” on June 01, 2018. Seekingalpha.com‘s news article titled: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q1 2018 Results – Earnings Call Transcript” with publication date: May 14, 2018 was also an interesting one.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company has market cap of $87.91 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.